Huihe Medical Completes Series B+ Financing, Establishes Itself as a Leading Full-Industry Platform in Cardiovascular Intervention

VCBeat (WeChat ID: vcbeat) has learned that,Recently,Shanghai Huihe Healthcare Technology Co., Ltd. (hereinafter referred to as "HuiHe Healthcare") announced the completion of its Series B+ financing round at a valuation of nearly RMB 5 billion, exclusively invested by Sherpa Capital, a renowned healthcare-focused investment fund.。

Since entering the structural heart disease field in 2018, HuiHe Healthcare’s first product, the K-Clip™ (Transcatheter Tricuspid Annuloplasty System), has successfully completed its initial humanitarian clinical trial and advanced to the confirmatory multicenter clinical trial phase. Through the continuous strengthening of its R&D capabilities, the company has established a comprehensive industrial platform for cardiovascular interventional devices, encompassing the entire lifecycle from R&D to clinical application and from pilot production to mass manufacturing.

On this platform, HuiHe Healthcare has integrated vascular interventional products, electrophysiology interventional products, and intelligent interventional products into its product pipeline through incubation, mergers, and strategic joint development. Among them, C-Wave™ (Vascular Calcification Shockwave Catheter System), the first product of Zhonghui Medical, a subsidiary of HuiHe Healthcare, is scheduled to enter a pivotal multicenter clinical trial in September. This will also be the second product from HuiHe Healthcare to enter a pivotal multicenter clinical trial.

Ms. Lin Lin, Founder and CEO of HuiHe Healthcare, stated:“Throughout its development, as a high-tech enterprise, HuiHe Healthcare has proven its capability to successfully translate its proprietary high-end medical devices from the laboratory to clinical practice, effectively addressing the pain points of both physicians and patients. Building upon this foundation, HuiHe now aims to scale up operations, continuously replicate successful products, and implement more proprietary technologies on its robust cardiovascular intervention platform. As a specialized healthcare investment fund, Sherpa Investment has consistently provided strong support for the growth of innovative domestic enterprises. We look forward to joining forces, remaining dedicated to innovation and exacting in quality, to deliver health and well-being to patients and clinicians.”

Mr. Daqing Cai, Founding Partner of Sherpa Capital, stated:“It is truly encouraging to see in China a platform-based medical device enterprise that boasts genuine global innovation capabilities, focuses on the treatment of major diseases such as cardiac and vascular interventions, and continuously launches innovative products to address unmet clinical needs: HuiHe Healthcare. Under the leadership of founder Lin Lin, HuiHe Healthcare has distinguished itself among the top tier in both innovative spirit and execution capability. Sherpa Capital is honored to be a shareholder of HuiHe Healthcare and will fully support the company’s commitment to independent innovation in the future, bringing the promise of better health to countless patients with cardiovascular diseases.”

HuiHe Healthcare is a cardiovascular interventional platform company with independent innovation capabilities, featuring independently developed, world-leading products in the fields of cardiac intervention, vascular intervention, electrophysiology intervention, and interventional surgical robotics. In cardiac intervention, the tricuspid annulus repair system K-Clip™, invented by HuiHe Healthcare, has successfully completed its initial clinical trial and garnered widespread clinical recognition. The company has contributed to multiple influential publications and industry consensus documents. The system has now entered the pivotal clinical trial phase and is poised to initiate global multi-center clinical trials. Its vascular intervention and other interventional products will sequentially enter clinical development. HuiHe Healthcare employs over 250 staff, including more than 120 R&D personnel and over 10 medical professionals. The company holds more than 130 patents, comprising 2 PCT patents and 3 North American patents. HuiHe Healthcare maintains industry-leading advantages in the R&D and manufacturing of vascular delivery systems, the integration of medical and technological expertise, large-scale production, and global commercialization.

Sherpa Capital is a specialized fund dedicated to early-stage healthcare investments. Adhering to an investment philosophy centered on building an industry ecosystem, the firm constructs its portfolio to address critical unmet medical needs. Grounded in a deep understanding of major disease therapeutic areas, it strategically deploys capital along the industry's vertical depth and across upstream and downstream sectors. By actively sharing operational expertise and a forward-looking perspective across the entire value chain with portfolio companies, the team proactively fosters internal and external synergies, empowering enterprises to achieve rapid growth in both business performance and valuation while securing leading positions in their respective niche markets. Having backed industry-leading companies across segments such as healthcare services, pharmaceuticals, gene technology, and medical devices, the firm has cultivated comprehensive resource advantages encompassing project sourcing, post-investment value-added services, and exit pathways. From 2011 to 2020, spanning four fund vintages and honed through over 100 healthcare projects, we have been privileged to partner with and grow alongside numerous outstanding entrepreneurs.